Home > Resources > Whitepapers > How Cellular is Enabling the Digital Supply Chain

How Cellular is Enabling the Digital Supply Chain

January 12, 2020

Supply chains grow more and more complex every day. In response, manufacturers and shippers have been eagerly exploring digital tools that provide actionable insight into the location and condition of in-transit goods. Although there are many technology options when it comes to building a digital supply chain, one type of solution stands out as the most reliable and cost-effective: cellular.

I'm For Real

Enter your details once to access all our information and resources

 

Spotlight

Pharmaceutical Solutions Industry Ltd "PSI"​

Dedicated to the development and manufacturing of pharmaceutical solutions with international quality standards, Pharmaceutical Solutions Industry Ltd. is a fully integrated pharmaceutical company thriving on a culture of innovation and excellence. 

 Pharmaceutical Solutions Industry is the leading, and the largest producer of a wide range of sterile IV solutions in the MENA region. 

Headquartered in Jeddah, Saudi Arabia, PSI has successfully grown to expand its portfolio catering to the needs of both domestic and international markets. 

As one of the Arab world's pioneering pharmaceutical companies, we are committed to providing the global healthcare market with life saving solutions. 

 PSI philosophy on the pharmaceutical production is that world competitive results can only be obtained with the best people, processes and technology. 

 With a workforce of 600 employees in addition to several full time consultants, PSI paves its way from planning to production for the quality, sa

OTHER WHITEPAPERS
news image

Assessing drug target association from biological evidences

whitePaper | July 7, 2022

The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules.

Read More
news image

Reimagining the pharma landscape with design thinking

whitePaper | July 29, 2021

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Read More
news image

2020 Prescription Drug List

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

Read More
news image

Blockchain technology in the pharmaceutical industry

whitePaper | March 11, 2022

Blockchain technology is accelerating digital transformation across multiple industries, including the pharmaceutical industry.

Read More
news image

QbD and PAT in Biopharmaceutical Development

whitePaper | July 12, 2022

As the pharmaceutical industry tries to embrace the methodologies of quality by design (QbD) provided by the FDA ’s process validation (PV) guidance (1) and International Conference on Harmonization.

Read More
news image

The Next Generation of Rare Disease Drug Policy

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

Read More

Assessing drug target association from biological evidences

whitePaper | July 7, 2022

The full drug target profile identification is many times a necessary step in drug development process. Recently, the move to a more holistic approach in drug discovery has resulted in the increasing use of cell-based assays to discover new biologically active small molecules.

Read More

Reimagining the pharma landscape with design thinking

whitePaper | July 29, 2021

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Read More

2020 Prescription Drug List

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

Read More

Blockchain technology in the pharmaceutical industry

whitePaper | March 11, 2022

Blockchain technology is accelerating digital transformation across multiple industries, including the pharmaceutical industry.

Read More

QbD and PAT in Biopharmaceutical Development

whitePaper | July 12, 2022

As the pharmaceutical industry tries to embrace the
methodologies of quality by design (QbD) provided
by the FDA ’s process validation (PV) guidance (1) and
International Conference on Harmonization.

Read More

The Next Generation of Rare Disease Drug Policy

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the
country or one in which “there is no reasonable expectation” of recovering research and
development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis,
and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

Read More
More Whitepapers

Spotlight

Pharmaceutical Solutions Industry Ltd "PSI"​

Dedicated to the development and manufacturing of pharmaceutical solutions with international quality standards, Pharmaceutical Solutions Industry Ltd. is a fully integrated pharmaceutical company thriving on a culture of innovation and excellence. 

 Pharmaceutical Solutions Industry is the leading, and the largest producer of a wide range of sterile IV solutions in the MENA region. 

Headquartered in Jeddah, Saudi Arabia, PSI has successfully grown to expand its portfolio catering to the needs of both domestic and international markets. 

As one of the Arab world's pioneering pharmaceutical companies, we are committed to providing the global healthcare market with life saving solutions. 

 PSI philosophy on the pharmaceutical production is that world competitive results can only be obtained with the best people, processes and technology. 

 With a workforce of 600 employees in addition to several full time consultants, PSI paves its way from planning to production for the quality, sa

Events

WORLD VACCINE CONGRESS EUROPE 2022

Conference